
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp has demonstrated impressive growth potential, with adjusted sales estimates for YUTREPIA now projected at peak sales of $1.7 billion to $2 billion, reflecting stronger than anticipated uptake among patients with pulmonary hypertension. The successful launch of YUTREPIA has enabled Liquidia to achieve operating profitability within the first full quarter of its commercial release, supported by compelling data on patient outcomes such as a significant increase in the six-minute walk distance. Additionally, the favorable tolerability profile of the L606 device, coupled with insights on the strategic use of the drug sotatercept, reinforces Liquidia's competitive edge in addressing unmet medical needs within the pulmonary hypertension market.
Bears say
Liquidia Corp faces considerable legal risks that threaten the exclusivity of its primary revenue source, YUTREPIA, particularly due to ongoing lawsuits regarding patent rights. The outcome of these legal challenges, especially concerning the '327 patent with a potential expiration in 2042, poses significant downside risk to the company’s financial stability and its future growth prospects. Additionally, even a favorable resolution for the long-term operations of YUTREPIA may not prevent short-term disruptions in sales, contributing to the stock's current valuation discount relative to its growth potential.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares